Appeal No. 2003-2084 Page 4
Application No. 08/241,061
prevent the crosstalk, i.e., the undesirable interactions between ligand
receptors and uncomplementary ligand analogue conjugates.
Specification, page 8.
The crosstalk inhibitors of the present invention are described as follows:
The crosstalk inhibitor, which resembles the linkage chemistry of
the ligand analogue conjugates, competes with the linkage chemistry of
the ligand analogue conjugates for binding to the terminal solid phase
ligand receptor. With the proper crosstalk inhibitor and crosstalk inhibitor
concentration, the competition is shifted toward binding of the crosstalk
inhibitor and not of the uncomplementary ligand analogue conjugates.
The crosstalk inhibitor should compete very poorly with the
complementary ligand analogue conjugate for the solid phase ligand
receptor because the affinity of the ligand receptor for the complementary
ligand analogue conjugate is much higher.
How closely the chemical structure of the crosstalk inhibitor must
resemble the linkage chemistry of the ligand analogue depends on the
affinity of the ligand receptor for the uncomplementary ligand analogue
conjugate. The crosstalk inhibitor may be free in solution or bound to a
protein or polymer. When the crosstalk inhibitor is attached to a protein or
polymer, it can bind multivalently to the solid phase ligand receptor as can
the ligand analogue conjugate. Thus, the multivalent crosstalk inhibitor
can better compete with the uncomplementary ligand analogue conjugate
than the monovalent crosstalk inhibitor.
Specification, pages 9-10.
As seen from claims 98 and 99, the claimed invention is directed to a
composition that comprises a ligand analogue conjugate(s), and a crosstalk inhibitor
with or without a ligand receptor. Ligand analogue conjugate is defined as “[a]
conjugate of a ligand analogue and a signal development element, a protein,
polypeptide, or polymer.” Specification, page 11, lines 14-22.
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Last modified: November 3, 2007